HOUSE 1375118th CongressReferred to the Subcommittee on Health.
EFFECTIVE Act
- Last Action
- 3/10/2023
Actions
- 2023-03-10Referred to the Subcommittee on Health.
- 2023-03-03Referred to the House Committee on Energy and Commerce.
- 2023-03-03Introduced in House
- 2023-03-03Introduced in House
CRS Summary
As of 2023-03-03 (00)
Ensuring the FDA Fully Examines Clinical Trial Impact and Vitalness before Endorsement Act or the EFFECTIVE Act
This bill specifies that the Food and Drug Administration may deny an application for a new opioid analgesic drug (i.e., opioid medication) upon a determination that the drug does not provide a significant advantage with respect to safety or effectiveness as compared to other drugs.
Cosponsors (5)
- Daniel Meuser (R-PA)
- Ann Kuster (D-NH)
- Daniel Kildee (D-MI)
- Josh Harder (D-CA)
- Brittany Pettersen (D-CO)
Sourced from Congress.gov (public domain).
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.